Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10766120 | 0.86 | ALDH1A1 (0.43) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL18485267 | 0.79 | MAPT (0.50) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL11600529 | 0.78 | MAPT (0.54) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL6691525 | 0.75 | MAPT (0.55) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL14805661 | 0.74 | MAPT (0.46) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL9731246 | 0.73 | MAPT (0.38) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL8371416 | 0.71 | MAPT (0.50) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL9731178 | 0.70 | MAPT (0.46) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL15665083 | 0.70 | MAPT (0.42) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 | |
| SCHEMBL2954045 | 0.70 | MAPT (0.42) | MAPTKDM4EHSD17B10ALDH1A1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | MAPT 4871/4885KDM4E 1199/4885HSD17B10 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.